Controlled Dangerous Substances and Treatment of Chronic Pain and Long-Term Oxygen Use Patients (Continuity of Care Act of 2022)
The legislation is expected to have a significant impact on the framework of state health laws by providing enhanced protections for both patients and prescribers. It allows for the continued treatment of patients without fear of legal repercussions if healthcare providers are compliant with the new regulations. This can potentially lead to improved patient outcomes by ensuring prescription continuity, especially in circumstances where patients may lose access to their previous providers due to various reasons, including change of insurance or relocation.
Senate Bill 865, named the 'Continuity of Care Act of 2022,' addresses the prescribing and management of controlled dangerous substances, particularly focusing on the treatment of patients suffering from chronic pain and those requiring long-term oxygen therapy. The bill aims to amend existing regulations to facilitate the ongoing care of patients transitioning between healthcare providers while ensuring they continue to receive their prescribed medications without abrupt changes. It establishes that healthcare providers must make a good-faith effort to maintain a patient's previous treatment regimen and document the necessary evaluations and prescribed dosages in their medical records.
Despite its potential benefits, SB865 has faced some criticism. Opponents express concern that while the bill seeks to protect patients from abrupt changes in treatment, it does not adequately address the risks of prescription misuse and the ongoing opioid crisis. Critics argue that the provisions allowing for the continuation of opioid prescriptions could inadvertently contribute to greater problems of dependency or overdose if not managed with sufficient safeguards. The discussions suggest a need for a balanced approach that ensures patient access to necessary medications while implementing stricter monitoring to prevent abuse.